These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 8017004)

  • 1. [The immunomodulating action of bestatin in the combined therapy of bladder cancer patients].
    Neprina GS; Panteleeva ES; Vatin OE; Kariakin OB
    Urol Nefrol (Mosk); 1994; (2):34-8. PubMed ID: 8017004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bestatin treatment enhances the recovery of radiation induced impairments of the immunological reactivity of the blood lymphocyte population in bladder cancer patients.
    Blomgren H; Edsmyr F; von Stedingk LV; Wasserman J
    Biomed Pharmacother; 1986; 40(2):50-4. PubMed ID: 3756312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological and haematological monitoring in bladder cancer patients receiving adjuvant bestatin treatment following radiation therapy. A prospective randomized trial.
    Blomgren H; Edsmyr F; Esposti PL; Näslund I
    Biomed Pharmacother; 1984; 38(3):143-9. PubMed ID: 6383491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Partial review of immunotherapeutic pharmacology in stem cell transplantation.
    Bierman PJ; Abe F; Buyukberber S; Ino K; Talmadge JE
    In Vivo; 2000; 14(1):221-36. PubMed ID: 10757081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The immune homeostasis of patients with prostatic cancer on hormonal chemotherapy, radiation treatment and immunological action].
    Panteleeva ES; Sviridova TV; Neprina GS; Sirotkina NP
    Urol Nefrol (Mosk); 1996; (1):28-31. PubMed ID: 8659039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant bestatin (Ubenimex) treatment following full-dose local irradiation for bladder carcinoma.
    Blomgren H; Esposti PL; Näslund I; Johansen L; Lemming O
    Acta Oncol; 1990; 29(6):809-12. PubMed ID: 2223154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes of the blood lymphocyte population in cancer patients treated with bestatin, a new immunomodulator. A phase I study.
    Blomgren H; Strender LE; Edsmyr F
    Biomedicine; 1980 Dec; 32(4):178-85. PubMed ID: 7470579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bestatin therapy of patients with atopic dermatitis.
    Thestrup-Pedersen K; Cramers M; Kongsholm H; Zachariae H
    Acta Derm Venereol; 1983; 63(6):549-52. PubMed ID: 6198850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulating properties of bestatin in cancer patients. A phase II trial.
    Mathé G; Umezawa H; Misset JL; Brienza S; Canon C; Musset M; Reizenstein P
    Biomed Pharmacother; 1986; 40(10):379-82. PubMed ID: 3495299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The intravesical administration of BCG vaccine in treating recurrent superficial bladder cancer].
    Panteleeva ES; Neprina GS; Vatin OE; Kariakin OB; Safiullin KN
    Urol Nefrol (Mosk); 1997; (2):29-32. PubMed ID: 9206879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulatory and therapeutic properties of bestatin in mice.
    Talmadge JE; Lenz BF; Pennington R; Long C; Phillips H; Schneider M; Tribble H
    Cancer Res; 1986 Sep; 46(9):4505-10. PubMed ID: 2942238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A new antitumor drug with immunomodulating activity, ubenimex (bestatin)].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 1987 Jul; 14(7):2385-91. PubMed ID: 3496857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of bestatin on immuno-suppressive acidic protein in patients with stomach cancer].
    Ishii T; Takeshita K; Sunagawa M; Habu H; Hoshi K
    Gan To Kagaku Ryoho; 1984 Aug; 11(8):1585-90. PubMed ID: 6476836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical studies of bestatin on genitourinary cancer].
    Ichikawa T; Hirokawa I; Ishihara Y
    Jpn J Antibiot; 1985 Jan; 38(1):166-78. PubMed ID: 3989976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant Bestatin immunotherapy in patients with transitional cell carcinoma of the bladder. Clinical results of a randomized trial.
    Blomgren H; Näslund I; Esposti PL; Johansen L; Aaskoven O
    Cancer Immunol Immunother; 1987; 25(1):41-6. PubMed ID: 3594491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical evaluation of bestatin (NK-421) supplementing radiotherapy in the treatment of lung cancer].
    Hamada F; Imajo Y; Inomata Y; Ichiyanagi A; Ashida C; Gose K; Imanaka K; Takada Y; Kimura S; Ogawa Y
    Nihon Gan Chiryo Gakkai Shi; 1983 Aug; 18(5):1175-80. PubMed ID: 6663170
    [No Abstract]   [Full Text] [Related]  

  • 17. [Immunotherapy with bestatin for acute non-lymphocytic leukemia (ANLL) in adults].
    Kurita S; Ota K; Yamada K; Massaoka T; Uzuka Y; Ogawa N
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2742-50. PubMed ID: 6508324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Experimental and clinical studies of bestatin as an immunomodulator].
    Miwa H; Oka T; Tsurumi T; Sakae Y; Orita K
    Gan To Kagaku Ryoho; 1982 Jul; 9(6):1019-24. PubMed ID: 7184437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The need of prolonged BCG treatment in superficial bladder cancer is suggested by the development of a peripheral immune response induced by BCG].
    Shekarsarai H; Zlotta AR; Drowart A; Van Vooren JP; De Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K
    Acta Urol Belg; 1997 Mar; 65(1):1-4. PubMed ID: 9245197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Phase I study of Bestatin: (I) A clinical study on determination of an optimal dose of Bestatin].
    Saito K; Miyasato H; Tajima K; Ikeda S
    Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt):211-7. PubMed ID: 6881973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.